biostudies-literatureUnknown10Palma AAbnormalities in myelination are associated to behavioral and cognitive dysfunction in neurodevelopmental psychiatric disorders. Thus, therapies to promote or accelerate myelination could potentially ameliorate symptoms in autism. Clemastine, a histamine H1 antagonist with anticholinergic properties against muscarinic M1 receptor, is the most promising drug with promyelinating properties. Clemastine penetrates the blood brain barrier efficiently and promotes remyelination in different animal models of neurodegeneration including multiple sclerosis, ischemia and Alzheimer's disease. However, its role in myelination during development is unknown. We showed that clemastine treatment during development increased oligodendrocyte differentiation in both white and gray matter. However, despite thFrontiers in cell and developmental biology841548https://www.ebi.ac.uk/biostudies/studies/S-EPMC8970281biostudies-literatureClemastine Induces an Impairment in Developmental Myelination.PMC8970281Chara JCOtxoa-de-Amezaga ARuiz-Jaen FMontilla AMatute CPerez-Samartin APalma APlanas AMDomercq MfalseClemastine Induces an Impairment in Developmental Myelination.Abnormalities in myelination are associated to behavioral and cognitive dysfunction in neurodevelopmental psychiatric disorders. Thus, therapies to promote or accelerate myelination could potentially ameliorate symptoms in autism. Clemastine, a histamine H1 antagonist with anticholinergic properties against muscarinic M1 receptor, is the most promising drug with promyelinating properties. Clemastine penetrates the blood brain barrier efficiently and promotes remyelination in different animal models of neurodegeneration including multiple sclerosis, ischemia and Alzheimer's disease. However, its role in myelination during development is unknown. We showed that clemastine treatment during development increased oligodendrocyte differentiation in both white and gray matter. However, despite th2022-01-01T00:00:00Z20222025-06-01T01:34:08.436Z2025-06-01T01:34:08.436ZS-EPMC89702813537234110.3389/fcell.2022.841548